GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results.

Here's the list of options activity happening in today's session: These bullet-by-bullet explanations have been constructed ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91.84 which represents a slight increase of $0.19 or 0.21% from the prior close of $91.65. The stock opened at $92.01 and ...

Gilead Sciences’ Livdelzi (seladelpar) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with the rare liver disease primary biliary cholangitis (PBC) ...

The drug has given promising results for the treatment of multiple myeloma, a rare form of blood cancer. The market for such ...